Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
NCT05924477
Recruiting
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: University of California San Francisco, San Francisco, California +7 locations
Conditions: Glaucoma
Register for Updates
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
NCT02991469
Recruiting
Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this population. Secondary Objective: To describe the pharmacodynamics (PD) profile, the efficacy, and the long term safety of sarilumab in patients with sJIA.
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
06/23/2025
Locations: Investigational Site Number : 0320004, San Miguel de Tucumán, Tucumán +26 locations
Conditions: Juvenile Idiopathic Arthritis
Register for Updates
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273
Recruiting
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +48 locations
Conditions: Large B-cell Lymphoma
Register for Updates
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
NCT04928261
Recruiting
The activity of trastuzumab in early-stage, HER2-positive breast cancer, has been demonstrated in many studies, with meta-analyses showing that in combination with a variety of chemotherapy backbones, trastuzumab reduces the risk of recurrence by nearly half, and death by a third. However, treatment with trastuzumab can result in cardiotoxicity, including heart failure, as well as the significant cost of treatment and the requirement for patients to attend the chemotherapy unit for treatment eve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: The Ottawa Hospital Cancer Centre, Ottawa, Ontario
Conditions: Breast Cancer
Register for Updates
Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study
NCT04973397
Recruiting
The proportion of noncardiac surgeries performed as same-day surgery is increasing worldwide, with more complex surgeries being performed on higher risk patients in the outpatient setting. Little is known on the risk factors, incidence and prognosis of patients undergoing same-day noncardiac surgery. The main objective of this study is to inform on the incidence and risk factors of cardiovascular and other adverse events after same-day surgery and to develop risk prediction tools to better infor... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
06/20/2025
Locations: Wake Forest Baptist Medical Centre, Winston-Salem, North Carolina +15 locations
Conditions: Preoperative Care, Surgery--Complications, Myocardial Infarction
Register for Updates
All in the Family: Promoting Family Function Through Physical Activity
NCT06098716
Recruiting
The goal of this trial is to find out whether adding identity-building and self-regulation training to basic healthy-living education helps families with inactive children (ages 6-12) become more cohesive and physically active. The main question it aims to answer is: Does the identity + self-regulation + education program improve family cohesion more than (a) self-regulation + education or (b) education alone? Researchers will compare three groups-identity+self-regulation+education (ID), self-... Read More
Gender:
ALL
Ages:
Between 6 years and 12 years
Trial Updated:
06/20/2025
Locations: University of Victoria, Victoria, British Columbia
Conditions: Physical Activity, Family Functioning
Register for Updates
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT05936359
Recruiting
This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Royal Brisbane and Women'S Hospital, Herston, Queensland +28 locations
Conditions: Myeloproliferative Neoplasms
Register for Updates
Single Fractions SBRT for Prostate Cancer
NCT04004312
Recruiting
It is a phase I study of radical hypofractionation delivering one single fraction of SBRT in patients with low- and favorable intermediate-risk prostate cancer that will undergo placement of the SpaceOAR hydrogel prior to treatment. Our hypothesis is that treatments can be safely delivered in one single fraction using SBRT provided the separation between the prostate and rectum is increased using the hydrogel
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: McGill University Health Centre-Cedars Cancer Centre, Montréal, Quebec
Conditions: Prostate Cancer
Register for Updates
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer
NCT04249154
Recruiting
Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic. Although surgery can be curative in patients evidencing pathological high-risk disease (extracapsular extension, seminal vesicle involvement, positive surgical margins), a large proportion will develop biochemical failure within years from the surgical procedure. The failure rate is even more pronounced in those patients that present with high prostate... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: McGill University Health Centre- Cedars Cancer Centre, Montreal, Quebec +1 locations
Conditions: Prostate Cancer
Register for Updates
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596
Recruiting
This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection phase followed by an adaptive design continuation. The study is comprised of 2 cohorts. Cohort 1 will include participants who have not received... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +169 locations
Conditions: Metastatic Urothelial Cancer
Register for Updates
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT06668181
Recruiting
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
06/19/2025
Locations: Ja0005 50646, Calgary, Not set +19 locations
Conditions: Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
Register for Updates
In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma
NCT02811523
Recruiting
Sarcoma which has spread to the lungs is most often treated with surgery. Even with surgery, most patients will not be cured and will die from their disease, probably because of small cancer cells that are present in the lungs at the time of surgery, but cannot be seen or detected. It is for this reason that we are looking for a better treatment. Giving chemotherapy after surgery is generally not recommended because it has significant side effects and no benefit has been proven. This study is i... Read More
Gender:
ALL
Ages:
Between 0 years and 64 years
Trial Updated:
06/19/2025
Locations: Princess Margaret Cancer Centre, Toronto, Not set
Conditions: Bone Sarcoma, Soft Tissue Sarcoma, Pulmonary Metastases
Register for Updates